Weekender: Biden nominates Robert Califf to return as FDA head

Signup | Forward Weekender Nov.​ 13,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — ISPOR The Future of HEOR and its Global Impact As the complexity of healthcare decision making continues to intensify, discover the unique strength of HE+OR. Download the White Paper.   Biden nominates Robert Califf to return as FDA head If confirmed by Congress, the cardiologist would return to lead an agency taxed by a heavy workload reviewing COVID-19 drugs and vaccines. Moderna founder unveils new drug company focused on a different kind of RNA Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday. The biotech is researching how to make medicines from transfer RNA molecules. Detailed Roche study results muddy another Alzheimer's hypothesis Data presented at an Alzheimer's meeting raised more questions about the seeming benefit of Roche and AC Immune's drug semorinemab, which they claim is the first of its kind to slow deterioration of memory. Sponsored Content by IQVIA IQVIA Omnichannel Navigator: A platform for informing smarter marketing decisions This year, the pharmaceutical industry will spend more on its promotional activities than any year before. It's estimated that the total U.S. promotional spend for 2021 will be around $30 billion. Mirati gives first look at KRAS drug combination in lung cancer Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras. J&J, world's largest drugmaker, plans to split in two The industry giant and mainstay of corporate America will separate its consumer health business from its drug and medical device units, which will retain the J&J brand.  Beam gets green light to begin first clinical test of base editing Alongside the milestone, the gene editing biotech also announced John Maraganore, who will soon step down as Alnylam's CEO, will join its board. BROUGHT TO YOU BY — Regulatory Affairs Professionals Society The support you need to advance your career RAPS offers members the latest news and trends in the healthcare product industry to continue developing in their careers. Become a part of a diverse global community and all RAPS offers today. Learn more. From Our Library Trendline The ongoing developments in the COVID-19 vaccine Webinar - on demand Important ADME & Drug-Drug Interaction Considerations for Successful Drug Development Xenotech Trendline How cancer research is changing the pharma and biotech sectors Webinar - on demand Curating Data to Enable Patient Care Innovation IQVIA View all resources Best of What We're Reading Financial Times AstraZeneca to take profits from Covid vaccine sales FiercePharma Lundbeck to cut 300 jobs to fuel CGRP migraine drug growth The Washington Post Top Biden health officials push to make coronavirus booster shots available to all adults Nature COVID antiviral pills: what scientists still want to know Reuters Moderna COVID-19 vaccine patent dispute headed to court, U.S. NIH head says NPR Oklahoma Supreme Court throws out opioid ruling against Johnson & Johnson Suggest a story we should read Upcoming Events The Dangers of Decentralized Labeling & Your Supply Chain: How 3 Companies Avoided Common Pitfalls Nov. 18, 2021 - Nov. 18, 2021 | Webinar 2pm ET Future Perspectives for Biopharma Quality: A Focus on People, Process, and Proactive Risk Mitigation Nov. 16, 2021 - Nov. 16, 2021 | Webinar 2pm ET Getting Your Data Aggregation Contract Right in Pharma Dec. 2, 2021 - Dec. 2, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip